<DOC>
	<DOCNO>NCT01554696</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ASP015K moderate severe rheumatoid arthritis subject methotrexate-inadequate responder ( MTX-IR ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy ASP015K Moderate Severe Rheumatoid Arthritis Subjects Who Have Had Inadequate Response Methotrexate</brief_title>
	<detailed_description>Subjects treatment group continue take concomitant oral weekly dose methotrexate ( MTX ) addition daily ASP015K matching placebo , take orally food , daily 12 week randomization .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subject rheumatoid arthritis ( RA ) diagnose accord 1987 revised ACR criterion least 6 month prior Screening Subject treat oral methotrexate ( MTX ) minimum 90 day stable dose 28 day prior first dose study drug ≥6 tender/painful joint ; ≥6 swell joint Subject meet ACR 1991 Revised Criteria Global Functional Status RA Class I , II III Screening Baseline Subject 's medication take treatment RA must stable least 28 day prior start study Male female subject must willing comply contraception requirement well restriction regard egg sperm donation Female subject must breastfeed Screening study period , 60 day final study drug administration Subject agree participate another interventional study treatment Positive Mycobacterium tuberculosis ( TB ) test within 90 day Screening Abnormal chest xray indicative acute chronic infectious process malignancy Receipt live live attenuate virus vaccination within 30 day prior first dose study drug Known history positive test hepatitis B surface antigen ( HBsAg ) hepatitis C antibody history positive test human immunodeficiency virus ( HIV ) infection History autoimmune rheumatic disease , Sjogren 's syndrome Previous history clinically significant infection illness ( require hospitalization require parenteral therapy ) within 90 day Baseline visit , history illness would preclude participation study History malignancy , except successfully treat basal squamous cell carcinoma skin insitu carcinoma cervix Does meet specify washout criterion follow RA medication : gold , azathioprine , minocycline , penicillamine , etanercept , certolizumab , adalimumab , golimumab , infliximab , cyclophosphamide , leflunomide Subject previously use non antiTNF biologic diseasemodifying antirheumatic drug ( DMARD ) ( e.g. , anakinra , abatacept , rituximab , tocilizumab ) Previous intolerance Janus kinase ( JAK ) inhibitor Receipt intraarticular parenteral corticosteroid within 28 day prior first dose study drug currently take &gt; 30 mg oral morphine ( narcotic equivalent ) per day Absolute lymphocyte count ( ALC ) &lt; 750/mm3 Receipt plasma exchange therapy within 60 day prior start study drug Receipt investigational agent within 30 day 5 halflives , whichever longer , prior first dose study drug Receipt medication CYP3A substrates narrow therapeutic range within 14 day prior first dose study drug History heart failure , define New York Heart Association ( NYHA ) grade 3 great History long QT syndrome prolong QT interval Any ongoing severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , metabolic , endocrine , pulmonary , cardiac , neurological , infectious disease , ongoing illness would make subject unsuitable study . This include stomatitis , gastrointestinal ulcer , condition would preclude continued treatment methotrexate Subject condition possibly affect oral absorption ( e.g. , gastrectomy , malabsorption syndrome , clinically significant diabetic gastroenteropathy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>ASP015K</keyword>
</DOC>